TherapeuticsMD (TXMD) Given a $9.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a $9.00 target price on TherapeuticsMD (NASDAQ:TXMD) in a research note published on Wednesday morning. The firm currently has a buy rating on the stock.

Several other research firms have also issued reports on TXMD. BidaskClub upgraded TherapeuticsMD from a strong sell rating to a sell rating in a research report on Wednesday, October 25th. Jefferies Group restated a buy rating and issued a $15.00 price target on shares of TherapeuticsMD in a research report on Friday, September 8th. Noble Financial restated a buy rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Cantor Fitzgerald restated a buy rating and issued a $33.00 price target on shares of TherapeuticsMD in a research report on Monday, September 4th. Finally, Oppenheimer set a $10.00 price target on TherapeuticsMD and gave the stock a buy rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of Buy and a consensus target price of $14.88.

Shares of TherapeuticsMD (TXMD) traded down $0.11 on Wednesday, reaching $6.06. The company’s stock had a trading volume of 6,273,200 shares, compared to its average volume of 2,932,273. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business’s quarterly revenue was down 19.7% compared to the same quarter last year. During the same period last year, the company earned ($0.13) EPS. equities research analysts predict that TherapeuticsMD will post -0.37 earnings per share for the current fiscal year.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of TherapeuticsMD stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 23.92% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in shares of TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock valued at $112,783,000 after purchasing an additional 6,340,346 shares during the period. Bank of New York Mellon Corp raised its stake in shares of TherapeuticsMD by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock valued at $136,894,000 after purchasing an additional 2,985,846 shares during the period. Stifel Financial Corp raised its stake in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after purchasing an additional 1,622,668 shares during the period. Voya Investment Management LLC raised its stake in shares of TherapeuticsMD by 33.4% in the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock valued at $15,595,000 after purchasing an additional 741,588 shares during the period. Finally, State Street Corp raised its stake in shares of TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock valued at $23,647,000 after purchasing an additional 583,094 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.

WARNING: “TherapeuticsMD (TXMD) Given a $9.00 Price Target by Deutsche Bank Analysts” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/21/therapeuticsmd-txmd-given-a-9-00-price-target-by-deutsche-bank-analysts.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit